Seven resistant and 14 new mutations were detected in 82 BCR::ABL1‐positive ALL subjects pre‐therapy, and P‐loop mutations were most prevalent (n = 5) among resistant mutations. Here, ABL1 is linked to acute lymphoblastic leukemia.